Employing NCQA HEDIS® Measures for Major Depressive Disorder to Improve Health Plan Performance and Community Mental Health
Employing NCQA HEDIS® Measures for Major Depressive Disorder to Improve Health Plan Performance and Community Mental Health
On-Demand Webcast
Presenters/Q&A Cohosts
Sepheen C. Byron, MHS
Director, Performance Measurement
National Committee for Quality Assurance
Washington, DC
Jeffrey D. Dunn, PharmD, MBA
Formulary and Contract Manager
SelectHealth, Inc.
Murray, Utah
J. Craig Nelson, MD
Leon J. Epstein Professor of Psychiatry
University of California San Francisco
San Francisco, California
Participants who have successfully completed the live version of this activity are not eligible to receive credit for this enduring material.
Learning Objectives
After completing this activity, participants should be able to:
- Evaluate the clinical and economic consequences of major depressive disorder and treatment failure
- Outline the benefits, limitations, and roles of antidepressant medication classes and the factors involved in treatment selection
- Align managed care strategies, such as disease management programs and cost-sharing, with evidence-based care to promote patient compliance
- Apply depression-related HEDIS measures to improve health plan performance and patient adherence
Intended Learners
This activity is designed for managed markets physicians, pharmacists, and nurses.
Activity Overview
This on-demand webcast is available with synchronized slides and audio.
To be eligible for documentation of credit, participants must complete the educational activity, complete the 10-question online post-test with a score of 70% or better, and complete the evaluation form. After successful completion of the post-test and evaluation form online at www.naccme.com, participants may immediately print their documentation of credit.
There is no fee associated with this activity.
This educational activity is a knowledge-based activity.
Participants who have successfully completed the live version of this activity are not eligible to receive credit for these enduring materials.
Release Date: December 20, 2012
Expiration Date: December 20, 2013
Estimated time to complete: 1 hour
For questions regarding this educational activity, please call 609-371-1137.
Hardware/Software Requirements
All educational activities are accessible via a PC (Windows 2000/XP/Vista/7) or Mac (Mac OS 10.x or later) computer with current versions of the following browsers: Internet Explorer, Mozilla Firefox, Google Chrome or Safari. Windows Media Player or compatible alternative, sound card, and speakers are required for streamed audio. The latest version of the Adobe Flash Player is suggested (please download here) for video programs. A PDF reader is required for print publications. Please direct technical questions to webmaster@naccme.com.
Accreditation
In support of improving patient care, North American Center for Continuing Medical Education, LLC (NACCME) is accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
CME
NACCME designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CPE
This activity is approved for 1 contact hour (0.1 CEU) of continuing pharmacy education (UAN 276-999-12-037-H01-P).
Any participant wanting to file a grievance with respect to any aspect of a continuing pharmacy education activity accredited by NACCME may contact the Assistant Director, Accreditation Services, NACCME, in writing at 300 Rike Drive, Suite A, Millstone Township, NJ 08535. The Assistant Director, Accreditation Services will review the grievance and respond within 30 days of receiving the written statement. If the participant is unsatisfied with the response, an appeal to the Executive Director, Accreditation Services, NACCME, may be made for a second level of review.
CNE
This continuing nursing education activity awards 1.0 contact hour.
Provider approved by the California Board of Registered Nursing, Provider #13255 for 1.0 contact hour.
Nurse practitioners participating in this educational activity will earn an AMA PRA Category 1 Credit certificate of completion or ANCC contact hours through AANP's reciprocity agreements.
Nurse Planner: Susie Seaman, NP, Sharp Rees-Stealy Wound Clinic, San Diego, California
Independent Clinical Reviewer: Bradley N. Gaynes, MD, MPH, Professor of Psychiatry, University of North Carolina School of Medicine, Chapel Hill, North Carolina
Planning Committee
The planning commitee comprises Sepheen Byron, MHS, Jeffrey D. Dunn, PharmD, MBA, Bradley N. Gaynes, MD, MPH, J. Craig Nelson, MD, Thomas Schwartz, MD, and Susie Seaman, NP; and Stephen Chavez, Lindsay Halverson, Mike Kearney, Nick Lombardi, Randy Robbin, Lynn Rubin, and Jessica Steuerman, NACCME.
Financial Disclosure and Conflicts of Interest
According to the disclosure policy of NACCME, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of NACCME to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.
All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.
The faculty has reported the following:
Dr. Dunn: Consultant—ChemGenex Pharmaceuticals Ltd., Novartis Corp., Genentech, Inc., Dendreon Corp.
Dr. Nelson: Consultant— Bristol Myers Squibb, Corcept, Dey Pharma-Mylan, Eli Lilly, Lundbeck, Medtronic, Otsuka, Pfizer; Scientific Advisor—Avanir, Bristol Myers Squibb, Cenestra,Corcept, Eli Lilly; Stock shareholder—Atossa; Expert Witness—Finnegan, Henderson, Farabow, Garrett, Dunner on behalf of Eli Lilly
Dr. Schwartz: Grant/Research support—Cephalon, Cyberonics, Bristol Myers Squibb; Consultant—Dey, Pamlab; Promotional speakers bureau—Merck
Ms. Seaman: Scientific advisor—Mölnlycke Health Care; Promotional speakers bureau—Mölnlycke
Ms. Byron and Dr. Gaynes disclosed no relevant financial relationships with any commercial interests.
Mr. Chavez, Ms. Halverson, Mr. Kearney, Mr. Robbin, Ms. Rubin, and Ms. Steuerman have disclosed no relevant financial relationships with any commercial interests.
Mr. Lombardi: Stock shareholder—Inspire Pharmaceuticals, Inc., ViroPharma, Inc., Vertex Pharmaceuticals
NACCME requires faculty to inform participants whenever off-label/unapproved uses of drugs and/or devices are discussed in their presentations.
The faculty have disclosed that no off-label/unapproved uses of drugs and/or devices will be discussed in the presentations.
Privacy Policy
NACCME protects the privacy of personal and other information regarding participants, educational partners, and joint sponsors. NACCME and our joint sponsors will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the appropriate accrediting agency.
NACCME maintains physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.
Copyright © 2012 by North American Center for Continuing Medical Education, LLC. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from North American Center for Continuing Medical Education.
Grant Support
Supported by educational grants from Lilly USA, LLC and Otsuka America Pharmaceutical, Inc.
